Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody

Rosanna Di Paola, Roberto Di Marco, Emanuela Mazzon, Tiziana Genovese, Klaus Bendtzen, Battesimo Macrì, Ferdinando Nicoletti, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

Abstract

CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-α play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalClinical Immunology
Volume113
Issue number1
DOIs
Publication statusPublished - Oct 2004

Fingerprint

CD30 Ligand
Pleurisy
Carrageenan
Monoclonal Antibodies
Tumor Necrosis Factor-alpha
Inflammation
Tumor Necrosis Factor Receptors
Interleukin-1
Cytokines

Keywords

  • CD30L
  • Cytokine
  • Pleurisy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Di Paola, R., Di Marco, R., Mazzon, E., Genovese, T., Bendtzen, K., Macrì, B., ... Cuzzocrea, S. (2004). Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. Clinical Immunology, 113(1), 64-73. https://doi.org/10.1016/j.clim.2004.05.008

Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. / Di Paola, Rosanna; Di Marco, Roberto; Mazzon, Emanuela; Genovese, Tiziana; Bendtzen, Klaus; Macrì, Battesimo; Nicoletti, Ferdinando; Cuzzocrea, Salvatore.

In: Clinical Immunology, Vol. 113, No. 1, 10.2004, p. 64-73.

Research output: Contribution to journalArticle

Di Paola, R, Di Marco, R, Mazzon, E, Genovese, T, Bendtzen, K, Macrì, B, Nicoletti, F & Cuzzocrea, S 2004, 'Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody', Clinical Immunology, vol. 113, no. 1, pp. 64-73. https://doi.org/10.1016/j.clim.2004.05.008
Di Paola, Rosanna ; Di Marco, Roberto ; Mazzon, Emanuela ; Genovese, Tiziana ; Bendtzen, Klaus ; Macrì, Battesimo ; Nicoletti, Ferdinando ; Cuzzocrea, Salvatore. / Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. In: Clinical Immunology. 2004 ; Vol. 113, No. 1. pp. 64-73.
@article{c141650fa4244fd8b993fcfbf27a920b,
title = "Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody",
abstract = "CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-α play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.",
keywords = "CD30L, Cytokine, Pleurisy",
author = "{Di Paola}, Rosanna and {Di Marco}, Roberto and Emanuela Mazzon and Tiziana Genovese and Klaus Bendtzen and Battesimo Macr{\`i} and Ferdinando Nicoletti and Salvatore Cuzzocrea",
year = "2004",
month = "10",
doi = "10.1016/j.clim.2004.05.008",
language = "English",
volume = "113",
pages = "64--73",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody

AU - Di Paola, Rosanna

AU - Di Marco, Roberto

AU - Mazzon, Emanuela

AU - Genovese, Tiziana

AU - Bendtzen, Klaus

AU - Macrì, Battesimo

AU - Nicoletti, Ferdinando

AU - Cuzzocrea, Salvatore

PY - 2004/10

Y1 - 2004/10

N2 - CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-α play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.

AB - CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-α play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.

KW - CD30L

KW - Cytokine

KW - Pleurisy

UR - http://www.scopus.com/inward/record.url?scp=6044241772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044241772&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2004.05.008

DO - 10.1016/j.clim.2004.05.008

M3 - Article

C2 - 15380531

AN - SCOPUS:6044241772

VL - 113

SP - 64

EP - 73

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -